Risk factors of recurrent lumbar disk herniation: a single center study and review of the literature
…, T Kobayashi, T Nishimura, K Igarashi… - Clinical Spine …, 2015 - journals.lww.com
Background: The recurrence of lumbar disk herniation (LDH) is a major problem in the
treatment of LDH. The purpose of this study was to investigate the risk factors for recurrent LDH. …
treatment of LDH. The purpose of this study was to investigate the risk factors for recurrent LDH. …
[HTML][HTML] High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin-and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived …
…, T Murakami, Y Tome, K Kawaguchi, K Igarashi… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Follicular dendritic-cell sarcoma (FDCS) is a rare and recalcitrant disease. In the present study,
a patient-derived orthotopic xenograft (PDOX) mouse model of FDCS was established in …
a patient-derived orthotopic xenograft (PDOX) mouse model of FDCS was established in …
[HTML][HTML] Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived …
…, T Kiyuna, SM Dry, Y Li, AW James, K Igarashi… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Ewing's sarcoma is a rare and aggressive malignancy. In the present study, tumor from a
patient with a Ewing's sarcoma with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss …
patient with a Ewing's sarcoma with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss …
[HTML][HTML] Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
T Murakami, S Li, Q Han, Y Tan, T Kiyuna, K Igarashi… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Methionine dependence is due to the overuse of methionine for aberrant transmethylation
reactions in cancer. Methionine dependence may be the only general metabolic defect in …
reactions in cancer. Methionine dependence may be the only general metabolic defect in …
[HTML][HTML] Current and emerging targets in immunotherapy for osteosarcoma
Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients
with osteosarcoma have improved since the introduction of chemotherapy, outcomes of …
with osteosarcoma have improved since the introduction of chemotherapy, outcomes of …
[HTML][HTML] Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft …
K Kawaguchi, K Igarashi, S Li, Q Han, Y Tan, T Kiyuna… - Oncotarget, 2017 - ncbi.nlm.nih.gov
An excessive requirement for methionine termed methionine dependence, appears to be a
general metabolic defect in cancer. We have previously shown that cancer-cell growth can …
general metabolic defect in cancer. We have previously shown that cancer-cell growth can …
[HTML][HTML] Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient …
K Kawaguchi, K Igarashi, T Murakami, B Chmielowski… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Melanoma is a recalcitrant disease in need of transformative therapuetics. The present study
used a patient-derived orthotopic xenograft (PDOX) nude-mouse model of melanoma with …
used a patient-derived orthotopic xenograft (PDOX) nude-mouse model of melanoma with …
Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer
K Kawaguchi, K Miyake, Q Han, S Li, Y Tan, K Igarashi… - Cancer Letters, 2018 - Elsevier
Recombinant methioninase (rMETase) was previously administered as an injectable drug
to target methionine dependence of cancer. Recently, we observed that rMETase could be …
to target methionine dependence of cancer. Recently, we observed that rMETase could be …
[HTML][HTML] Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic …
K Kawaguchi, T Murakami, B Chmielowski, K Igarashi… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Melanoma is a recalcitrant disease. The present study used a patient-derived orthotopic
xenograft (PDOX) model of melanoma to test sensitivity to three molecularly-targeted drugs and …
xenograft (PDOX) model of melanoma to test sensitivity to three molecularly-targeted drugs and …
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung …
K Igarashi, K Kawaguchi, T Kiyuna, K Miyake… - Cell Cycle, 2018 - Taylor & Francis
In the present study, a patient-derived orthotopic xenograft (PDOX) model of recurrent
cisplatinum (CDDP)-resistant metastatic osteosarcoma was treated with Salmonella typhimurium …
cisplatinum (CDDP)-resistant metastatic osteosarcoma was treated with Salmonella typhimurium …